%0 Journal Article
%T 蒽环类和紫杉类联合方案与序贯方案在乳腺癌新辅助化疗中的疗效观察<br>Observation on the Efficacy of Anthracycline Combined with Taxane and Sequential Regimen in Neoadjuvant Chemotherapy of Breast Cancer
%A 吴茜
%A 孔德志
%A 何林
%A 宋玉华
%J Advances in Clinical Medicine
%P 1874-1882
%@ 2161-8720
%D 2020
%I Hans Publishing
%R 10.12677/ACM.2020.109282
%X <div style=\"text-align:justify;\">
	观察蒽环类和紫杉类联合方案与序贯方案在乳腺癌新辅助化疗中的疗效差异。回顾性分析2012年1月至2018年12月就诊于我院的405例单侧原发性乳腺癌女性患者的临床资料，按新辅助化疗所应用的方案划分为蒽环类、紫杉类联合组(299例)及蒽环类、紫杉类序贯组(106例)。入组患者都经过至少4个周期的新辅助化疗(neoadjuvant chemotherapy, NAC)。对两组方案的客观缓解率(objective response rate, ORR)和病理完全缓解率(pathologic complete response, pCR)进行比较，并比较不同分子亚型对ORR及pCR的影响。蒽环类、紫杉类联合方案与蒽环类、紫杉类序贯方案的ORR无统计学差异(P = 0.333 &gt; 0.05)，pCR无统计学差异(P = 0.650 &gt; 0.05)。Luminal A型、Luminal B型、Her-2过表达型及三阴型乳腺癌的ORR无统计学差异(P = 0.762 &gt; 0.05)、pCR具有统计学差异(P = 0.003 &lt; 0.05)。蒽环类和紫杉类联合方案与序贯方案疗效相仿，三阴型及Her-2过表达型乳腺癌较Luminal型乳腺癌对新辅助化疗的疗效更佳。<br />
To study the efficacy of anthracycline combined with taxane and sequential regimen in neoadjuvant chemotherapy of breast cancer, the clinical data of 405 female patients with unilateral primary breast cancer who received treatment in our hospital from January 2012 to December 2018 were analyzed retrospectively. According to the regimens used in neoadjuvant chemotherapy, they were divided into anthracycline combined with taxane group (299 cases) and anthracycline sequential taxane group (106 cases). All patients underwent neoadjuvant chemotherapy (NAC) for at least four cycles. Objective response rate (ORR) and pathologic complete response (pCR) were compared between the two groups, and the effects of different molecular subtypes on ORR and pCR were compared. There was no significant difference in ORR (P = 0.333 &gt; 0.05) and pCR (P = 0.650 &gt; 0.05) between anthracycline combined with taxane regimen and anthracycline sequential taxane regimen; There was no significant difference in ORR (P = 0.762 &gt; 0.05) and significant difference in PCR (P = 0.003 &lt; 0.05) among Luminal A, Luminal B, Her-2 over-expression and triple-negative breast cancers. The efficacy of anthracycline combined with taxane regimen is similar to that of sequential regimen. The efficacy of neoadjuvant chemotherapy in triple-negative and HER-2 over-expression breast cancers is better than that in Luminal breast cancers.
</div>
%K 乳腺癌，新辅助化疗，蒽环类，紫杉类<br>Breast Cancer
%K Neoadjuvant Chemotherapy
%K Anthracycline
%K Taxane
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=37516